Clinical Observation Of Lenalidomide Combined With Abiraterone In The Treatment Of Castration-resistant Prostate Cancer With Bone Metastases

BackgroundCastration-resistant prostate cancer(CRPC)has a poor prognosis,patients have a short survival time,and most are associated with bone metastasis symptoms.The main goal of the treatment of this disease is to delay the progression of the disease,improve the quality of life,and improve the survival time of patients.The first-line treatment for advanced CRPC is the combination of docetaxel and prednisone.Lenalidomide is an anti-tumor and immunomodulator,which is widely used in the treatment of various tumors.We tried to use lenalidomide combined with abiraterone to treat patients with bone metastasis CRPC.Objective1.Efficacy of lenalidomide combined with abiraterone in patients with bone metastasis CRPC.2.Safety of lenalidomide and abiraterone in patients with bone metastasis CRPC.MethodsEighty patients with CRPC who were admitted to the First Affiliated Hospital of Xinxiang Medical College and the Third Affiliated Hospital of Xinxiang Medical College from October 2015 to March 2016 were selected.According to different treatment schemes,they were divided into two groups,a control group of 40 patients: a cycle of 4 weeks,the patient took oral abiraterone 1000 mg/d once daily,combined with prednisone 5 mg twice daily.Observation group of 40 cases: 4 weeks as a cycle,the patient took oral abiraterone 1000 mg/d once daily,combined with prednisone 5 mg twice daily,1-21 days per cycle,daily oral Lenalidomide 25 mg.Both groups of patients were given zoledronic acid 4 mg intravenous drip during the treatment period,once every 28 days;patients who did not undergo orchiectomy continued to be given goserelin once every 28 days.ResultsThe median OS in the observation group and the control group was 25.3 months and 21.6 months,respectively,and the bone pain relief rate was 57.9% and 50.0%,respectively.There was no statistically significant difference between the two groups(P> 0.05).The median PSAPFS was 10.7 months and 8.7 months,and the median RPFS was 12.3 months and 9.6 months,respectively.The differences between the two groups were statistically significant(P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P> 0.05).Conclusion1.Compared with abiraterone alone,lenalidomide combined with abiraterone can improve the overall survival of patients and improve the remission rate of bone pain,but the difference between the two groups is not obvious.PSA progression-free survival and imaging progression-free survival can be extended,the difference is statistically significant.2.In terms of adverse reactions,the combination medication is similar to the medication alone,and the combination medication is safer.